Form 4: Aprea Therapeutics Executive Acquires Shares and Warrants

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, Inc., purchased 1,010 shares of common stock and acquired Tranche A and B warrants on March 13, 2024.

Summary

• On March 13, 2024, John P. Hamill, a Senior Vice President, CFO, and Principal Financial & Accounting Officer at Aprea Therapeutics, Inc., acquired 1,010 shares of common stock at a price of $7.29 per share.
• Following this transaction, Hamill directly owns 15,503 shares of Aprea Therapeutics' common stock.
• Hamill also acquired Tranche A and Tranche B warrants.
• The Tranche A warrants are for 505 shares with an exercise price of $7.29 per share (or $7.289 per share under certain conditions) and expire on March 13, 2027, with potential for earlier termination based on Phase 2 dose announcement for ATRN-119 and stock price performance.
• The Tranche B warrants are for 505 shares with an exercise price of $9.1125 per share (or $9.1115 per share under certain conditions) and expire on March 13, 2029, with potential for earlier termination based on Phase 2 dose announcement for APR-1051 and stock price performance.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. An executive purchasing shares and warrants suggests confidence, but the warrants' terms are tied to future milestones, introducing some uncertainty.

Positives

• Executive's purchase of shares and warrants could be interpreted as a sign of confidence in the company's future prospects.

Risks

• The warrants have conditions for early termination based on clinical trial milestones and stock price performance, which introduces uncertainty.

Future Outlook

The warrants' terms are tied to the announcement of Phase 2 doses for ATRN-119 and APR-1051, as well as the stock's VWAP reaching certain thresholds, suggesting these are key milestones for the company.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects. This Form 4 filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• It's common for executives in publicly traded biotech companies like Aprea Therapeutics to receive stock options and warrants as part of their compensation packages.
• The exercise prices and expiration dates of the warrants are typical for the industry, often tied to company milestones and stock performance.
• Comparing Aprea's warrant terms to those of similar companies like Mirati Therapeutics or Relay Therapeutics would provide a more detailed benchmark.

Stakeholder Impact

• Shareholders may view the executive's purchase as a positive signal.
• The warrant terms could incentivize management to achieve clinical and stock price milestones.

Next Steps

• Monitor Aprea Therapeutics' progress on Phase 2 dose announcements for ATRN-119 and APR-1051.
• Track the company's stock price performance to assess the likelihood of the warrants' early termination conditions being met.

Key Dates